medical research future fund logo

Medical Research Future Fund has $20 billion to spend. Here’s how we prioritise who gets what

Professor of Statistics, Queensland University of Technology

Professor of Health Economics, University of Oxford

Disclosure statement

Adrian Barnett receives funding from the Medical Research Future Fund and the National Health and Medical Research Council. He is a member of the NHMRC Research Committee; this article represents his own views.

Philip Clarke receives funding from the Medical Research Future Fund via grants held at the University of Melbourne.

Queensland University of Technology provides funding as a member of The Conversation AU.

University of Oxford provides funding as a member of The Conversation UK.

View all partners

The Medical Research Future Fund (MRFF) is a A$20 billion fund to support Australian health and medical research. It was set up in 2015 to deliver practical benefits from medical research and innovation to as many Australians as possible.

Unlike the other research funding agencies, such the National Health and Medical Research Council (NHMRC), most of the MRFF funding is priority-driven. It seeks to fund research in particular areas or topics rather than using open calls when researchers propose their own ideas for funding.

As the Nine newspapers outlined this week, researchers have criticised the previous Coalition government’s allocation of MRFF funds. There is widespread consensus the former health minister had too much influence in the allocation of funds, and there was limited and sometimes no competition when funding was directly allocated to one research group.

The current Health Minister, Mark Butler, has instituted a review . So how should the big decisions about how to spend the MRFF be made in the future to maximise its value and achieve its aims?

Read more: Nobel laureate Brian Schmidt's big ideas for how Australia funds and uses research

Assess gaps in evidence

Research priorities for the MRFF are set by the Australian Medical Research Advisory Board , which widely consults with the research sector.

However, most researchers and institutions will simply argue more funding is needed for their own research. If the board seeks to satisfy such lobbying, it will produce fragmented funding that aligns poorly with the health needs of Australians.

A better approach would be to systematically assemble evidence about what is known and the key evidence gaps. Here, the board would benefit from what is known as a “ value of information ” framework for decision-making.

This framework systematically attempts to quantify the most valuable information that will reduce the uncertainty for health and medical decision-making. In other words, it would pinpoint which information we need to allow us to better make health and medical decisions.

There have been attempts to use this method in Australia to help inform how we prioritise hospital-based research. However, we now need to apply such an approach more broadly.

Read more: COVID has left Australia's biomedical research sector gasping for air

Seek public input

A structured framework for engaging with the public is also missing in Australia. The public’s perspective on research prioritisation has often been overlooked, but as the ultimate consumers of research, they need to be heard.

Research is a highly complex and specialised endeavour, so we can’t expect the public to create sensible priorities alone.

One approach used overseas has been developed by the James Lind Alliance , a group in the United Kingdom that combines the public’s views with researchers to create agreed-on priorities for research.

This is done using an intensive process of question setting and discussion. Priorities are checked for feasibility and novelty, so there is no funding for research that’s impossible or already done.

The priorities from the James Lind Alliance process can be surprising. The top priority in the area of irritable bowel syndrome , for example, is to discover if it’s one condition or many, while the second priority is to work on bowel urgency (a sudden urgent need to go to the toilet).

While such everyday questions can struggle to get funding in traditional systems that often focus on novelty, funding research in these two priority areas could lead to the most benefits for people with irritable bowel syndrome.

Consider our comparative advantages

Australia is a relatively small player globally. To date, the MRFF has allocated around $2.6 billion , just over 5% of what the United States allocates through the National Institute of Health funding in a single year .

A single research grant, even if it involves a few million dollars of funding, is unlikely to lead to a medical breakthrough. Instead, the MRFF should prioritise areas where Australia has a comparative advantage.

This could involve building on past success (such as the research that led to the HPV, or human papillomavirus, vaccine to prevent cervical cancer), or where Australian researchers can play a critical role globally.

However, there is an area where Australian researchers have an absolute advantage: using research to improve our own health system.

A prime example would be finding ways to improve dental care access in Australia. For example, a randomised trial of different ways of providing insurance and dental services, similar to the RAND Health Insurance Experiment conducted in the United States in the 1970s.

This could provide the evidence needed to design a sustainable dental scheme to complement Medicare. Now that is something the MRFF should consider as a funding priority.

Read more: Expensive dental care worsens inequality. Is it time for a Medicare-style 'Denticare' scheme?

• Medical research
• Research funding
• Research priorities
• Science and research priorities

Project Offier - Diversity & Inclusion

Senior Lecturer - Earth System Science

Sydney Horizon Educators (Identified)

Deputy Social Media Producer

Associate Professor, Occupational Therapy

Research Funding

Medical research future fund.

The Medical Research Future Fund (MRFF) is a $20 billion vehicle for investment in health and medical research. It represents the single largest boost to research funding in Australia’s history. It supports research and innovation activities with the objective of improving the health and wellbeing of Australians.

The MRFF Initiatives team communicate MRFF funding opportunities and provide guidance and template documents, strategic application support and review, and eligibility and compliance checks.

The team assist with Chancellery sign off for letters of support and can coordinate support from other RIC divisions (including Business Development, Knowledge and Technology Transfer and Partnerships) in grant development. The team also facilitate acceptance of awards, negotiation and execution of agreements and variations and assists with managing reporting requirements.

All currently open schemes can be found  by clicking on 'Current Funding Opportunities' below. We also encourage you to check the MRFF Grant Opportunities Calendar which shows grant opportunities anticipated to open in the near future.

NEW: Funded rates of MRFF schemes between 2020-2022 (Appendix G)

The  MRFF Consumer Reference Panel has developed the  Principles for consumer involvement in research funded by the Medical Research Future Fund to encourage and support effective collaboration between consumers, researchers, research organisations and other health and medical research stakeholders.

• Current Funding Opportunities

View key dates as well as the links to our specific scheme pages for open MRFF grant opportunities

Research Grants Library

View successful applications donated by University of Melbourne applicants

Post Award Information (MRFF NHMRC-run schemes)

Find out how to accept and manage your MRFF (NHMRC) grant.

Post Award Information (MRFF Department of Industry-run schemes)

Find out how to accept and manage your MRFF (DoI) grant.

More Information

• Find out more about the Medical Research Future Fund, how it works, who manages it, all awarded MRFF proposals and other MRFF-related resources on the Department's website  here .
• The Medical Research Future Fund Act 2015 sets out rules for the fund, including the establishment of the Australian Medical Research Advisory Board (AMRAB) and compels it to consult the public. AMRAB sets the strategy and priorities for the Medical Research Future Fund and consults the public regularly before updating these.
• AMRAB sets the Australian Medical Research and Innovation Strategy every 5 years. It takes into account Australia's health needs and areas that need greater investment. The current Strategy (2016-2021) can be found  here .
• AMRAB sets the Australian Medical Research and Innovation Priorities every 2 years. The current Priorities (2022-2024) can be found here .
• Find out more about consultations  here .

Register your Notice of Intent (NOI)

Register here

Upcoming workshops

• EMCR Workshop Series: Accessing MRFF Funding

Useful media links

MTPConnect's 'Preparing Successful Commercialisation Funding Applications' webinar

University of Melbourne MRFF Success Stories

Stay connected, sign up to the university's mrff alert.

Stay up-to-date with MRFF related activities and new scheme announcements

For further information on previous, current and potential future schemes or to discuss how your research might attract MRFF funding.

MRFF Grant Opportunities Calendar

See what MRFF grant opportunities are open and what their status is.

• Accepting your grant
• Variations of the project agreement
• Transferring and leaving the University
• Australia–Germany Joint Research Cooperation Scheme (UA–DAAD)
• Bonn-Melbourne Research Excellence Fund
• Dyason Fellowships
• Early Career Researcher Grant
• Establishment Grants for ARC DECRAs
• Establishment Grants for ARC Future Fellows
• Hebrew University of Jerusalem – University of Melbourne: Call for Joint PhD Projects
• Manage your grant
• International Research Training Groups (IRTGs)
• Invertebrate management research seed funding scheme
• Joyce Lambert Antarctic Research Fund
• KU Leuven – Melbourne Call for Joint PhD Projects
• Berlin University Alliance – University of Melbourne: Call for joint PhD projects in Global Health
• Manchester – Melbourne Call for Jointly Awarded/Dual PhD Projects
• Mary Lugton Postdoctoral Fellowships
• Marles Medal
• McCoy Project PhD Scholarships
• McCoy Seed Fund
• Melbourne Postdoctoral Fellowships (record of scheme)
• McKenzie Postdoctoral Fellowships Scheme
• Melbourne Research Fellowships (Career Interruptions) Program
• Melbourne-Indonesia Research Partnership Program
• Woodward Medallists
• Shanghai Jiao Tong University – University of Melbourne: Joint PhD Projects with paired Seed Funding
• University of Toronto – University of Melbourne: International Research Training Group - Call for Proposals
• International Grants Accelerator Program
• UoM – CNRS Graduate Research Projects Scheme
• Woodward Medals
• Victoria-Germany Bilateral Academic Exchange Program
• Hokkaido – Melbourne Joint Research Workshops Fund
• University of Melbourne – University of Bonn: Call for joint PhD project proposals
• Manchester-Melbourne-Toronto Research Fund
• Osaka – Melbourne Joint Research Workshops Fund
• JSPS Open Partnership Joint Research Projects co-funding scheme
• Establishment Grants for ARC Industry Fellows
• RDS Grants Schedule Overview
• Nagoya– Melbourne Joint Research Workshops Fund
• Melbourne – A*STAR Call for collaborative PhD project proposals
• Marles Medallists
• Puzey Postdoctoral Fellowship
• Research Impetus Grants
• U.S. National Institutes of Health (NIH)
• DoD Agencies
• Wellcome Trust
• International Codes and Contacts
• EMCR Workshop Series FAQs
• Primary industry schemes
• Victorian Future Industries Fund
• CRC Program - Cooperative Research Centres
• Cooperative Research Centres Projects (CRC-Ps)
• CRC for Developing Northern Australia Project Funding Round
• National Environmental Science Program
• ARC Special Research Initiatives
• Modern Manufacturing Initiative - Manufacturing Translation
• Modern Manufacturing Initiative - Manufacturing Integration
• Modern Manufacturing Initiative - Manufacturing Collaboration
• Current Students

Medical Research Future Fund

About the mrff.

The Medical Research Future Fund (MRFF) is a once in a generation opportunity to significantly reshape the landscape of Australian medical research and innovation.

Australia has world leading health and medical research (HMR) and a world-class health system, but too often they operate in isolation from each other rather than as one system with the aim of a healthier community. The MRFF provides the opportunity to bridge the gap between the two, so that Australian medical research and innovation in partnership with health practitioners delivers the new practices, services and products needed to continue to improve the health, wellbeing and prosperity of Australians.

Funding  into  the MRFF

Established by legislation in August 2015, the Medical Research Future fund is an investment fund. Capital injections were made into the MRFF in successive financial years, with the target account balance of $20 billion being achieved in July 2020. The capital is invested and the earnings are available to fund health and medical research and innovation.

Funding from the MRFF

The first funding from the MRFF was announced in May 2017. More information on the funding announced so far is available here . This amount will grow rapidly over the next few years, from $121 million in 2017/18 to an estimated $579 million in 2020/21 and around $650 million each year thereafter.

Decisions about what to fund are made by the Minister for Health. The Minister is guided by an expert Advisory board, which is responsible for developing the MRFF’s Strategy and Funding Priorities.

Research Australia has been actively involved in the development of the MRFF from the time it was first proposed. We continue to engage with the Government and the Health Department about the MRFF and are following its progress closely to ensure that its objective of bridging the gap between research and the health system is being met.

The Advisory Board

Funding decisions are made by the Health Minister in accordance with the five-year Strategy and two yearly funding Priorities, which are determined by the MRFF Advisory Board. Consisting of the CEO of the NHMRC and up to seven other appointees, the Board as a whole is required to have expertise in:

• medical research;
• policy relating to health systems;
• management or delivery of health services;
• medical innovation;
• financing and investment;
• commercialisation;
• philanthropy; and
• consumer issues relating to health.

An outline of the MRFF Act

The MRFF is created by the Medical Research Future Fund Act 2015 .

What can be funded

Earnings on the MRFF’s capital are to be used to fund  medical innovation  and medical research , both of which are defined by section 5 of the Act.

Medical innovation  includes:

(a) the application and commercialisation of medical research for the purpose of improving the health and wellbeing of Australians; and (b) the translation of medical research into new or better ways of improving the health and wellbeing of Australians.

Who can be funded

Section 10 of the Act specifies that grants can be made to:

• States and Territories via the COAG Reform Fund;
• corporate Commonwealth entities (eg. the CSIRO);
• universities and medical research institutes; and
• corporations.

So you’re new to…the Medical Research Future Fund

• Share on Facebook
• Share on Twitter
• Share on Linkedin
• Share via email

Officials, advisers and grant winners talk through one of Australia’s most important health research funds

Next year, the Medical Research Future Fund will reach its 10th anniversary. Set up in 2015, it was intended to turbocharge Australian funding for health research through a long-term investment.

Research projects are paid for through interest on the fund’s value, which hit A$20 billion in 2020. Currently, the MRFF is doling out A$650 million annually, making it second only to the National Health and Medical Research Council’s (NHMRC’s) annual spending of around A$900m.

This article on Research Professional News is only available to Research Professional or Pivot-RP users.

Research Professional users can log in and view the article via this link

Pivot-RP users can log in and view the article via this link .

Medical Research Future Fund

The Medical Research Future Fund (MRFF) is a dedicated vehicle for priority investment in health and medical research. 

The MRFF demonstrates the Government's strong comittment to research and innovation. It provides a long term sustainable source of funding to improve health outcomes, qualities of life and health system sustainability.

MRFF funding calls and announcements are made periodically and support a variety of schemes. As new announcements are made, the details are provided on this page. 

The MRFF also supports our researchers to make the next big medical discoveries that benefit all Australians.

MRFF scheme information

MRFF funding calls and announcements are made periodically and support a variety of schemes. As new announcements are made, the details are provided on this page.

Details about the Medical Research Future Fund

• About the MRFF
• Current Funding Opportunities

Key Streams

In order to support activity towards each of the Priorities, the Government has funded a series of initiatives under four broad categories: Patients, Researchers, Missions and Translation. Missions are initiatives with specific, ambitious goals; in some instances, but not all, missions are designed with the objective to seek significant co-funding investments. In all other instances, the funding initiatives are defined as Programs.

• Patients The MRFF will deliver more advanced healthcare and medical technology that will improve the health of Australians
• Researchers The MRFF is supporting the best health and medical researchers to make breakthrough discoveries, develop their skills and progress their careers in Australia
• Missions Missions are programs of work with ambitious objectives that are only possible through major funding, leadership and collaboration
• Translation The MRFF funds research translation - turning research discoveries into new treatments and cures

Researcher Portal

Medical Research Future Fund

The Medical Research Future Fund (MRFF) is a $20B long-term investment supporting priority-driven Australian health and medical research. The MRFF aims to transform health and innovation to improve lives, build the economy and contribute to health system sustainability.

Proposed projects must closely align with the goals, objectives and intended outcomes of the Initiative and Grant Opportunity being applied to. Refer to section 1 of the guidelines for each Grant Opportunity for further information.

Please refer to the MRFF Grant Opportunities Calendar for information on forecast MRFF grant opportunities.

MRFF funding application templates and resources

Upcoming rounds

2023 childhood mental health research grant opportunity, 2023 multidisciplinary models of primary care grant opportunity streams 1, 2, 3 and stream 4, 2023 clinical trials activity, 2024 paediatric brain cancer research, 2023 innovative trials, 2024 indigenous health research, 2024 early to mid-career researchers, 2024 stem cell therapies, 2024 cardiovascular health, 2024 survivorship care and collaborative research prioritisation, 2024 international clinical trial collaborations grant opportunity, 2024 mental health research, 2024 dementia, ageing and aged care, 2024 maternal health and healthy lifestyles, 2024 enhancing medical device surveillance through registries, 2022 frontier health and medical research.

Pre-Award team - Research Services

E:  [email protected]

Faculty contacts

• ABLE: Xiaochun Liu and Greg Macpherson
• HMS: Lesley Ritter and Julia Kuliwaba
• SET: Angie Jarrad and Marie Lagadec

• Follow UNSW on LinkedIn
• Follow UNSW on Instagram
• Follow UNSW on Facebook
• Follow UNSW on WeChat
• Follow UNSW on TikTok

$5.7m for clinical trials

2024-04-17T10:03:00+10:00

Photo: Getty Images.

Three UNSW Sydney projects have been awarded funding under the government’s Medical Research Future Fund’s clinical trials activity initiative.

UNSW Sydney researchers have been awarded more than $5.7 million under the Australian government’s Medical Research Future Fund (MRFF) clinical trials activity initiative, with projects spanning spinal cord injury, stroke, and diabetic ketoacidosis.

Interim Dean of UNSW Medicine & Health Professor Adrienne Torda congratulated the UNSW researchers who received funding. 

“These grants will help UNSW researchers and our partners improve the quality of life and health outcomes for many. I am so proud the teams who were successful in this round of funding and look forward to supporting their studies,” Prof. Torda said. 

Reducing spinal cord injury pain 

UNSW Professor Sylvia Gustin from UNSW Science and NeuRA was awarded $2.22 million for a randomised placebo-controlled trial to investigate the efficacy of an interactive brain-computer interface neuromodulation treatment combined with transcranial direct current stimulation for people with spinal cord injury neuropathic pain. 

The team of Prof. Gustin will conduct a randomised clinical trial to examine the efficacy and mechanisms of an advanced interactive Brain-Computer Interface Neuromodulation (BCI-N) treatment combined with transcranial direct current stimulation (tDCS). The study has the potential to inform patient care across the spectrum of initial hospitalisation to home-based self-management.

“Given the deleterious impact of spinal cord injury neuropathic pain on the quality of life and the easy translation of our novel brain-technology intervention into accessible home use, the results of this clinical trial are expected to provide a sustainable advance in spinal cord injury pain management,” Prof. Gustin said.  

Improving outcomes for people with a debilitating form of stroke

Professor Jeremy Cohen from The George Institute for Global Health and UNSW Medicine & Health has received $1.9 million for a project that aims to improve the outcomes for younger people with a debilitating form of stroke, subarachnoid haemorrhage.

“A subarachnoid haemorrhage is a devastating type of stroke affecting around 2000 Australians a year, a third of whom will die from the condition with the remainder at risk of permanent disability. Up to 40 per cent of this often young and previously fit population are unable to return to their previous occupation,” Prof. Cohen said.

A common complication in this type of stroke is low blood levels of sodium (or hyponatremia) which occurs in up to two thirds of hospitalised patients. Hyponatremia is associated with a twofold increase in duration of hospital and ICU stay in these patients.

Previous work by Dr Jeremy Cohen, Director of the Wesley Hospital Intensive Care Unit and Honorary Professorial Fellow at The George Institute, confirmed that hyponatraemia during ICU admission is also significantly associated with worse levels of disability six months later.

This study will investigate if fludrocortisone, a low cost and well-established corticosteroid that regulates salt and water balance in the body, can prevent this fall in sodium and therefore improve outcomes in these patients.

Fluid therapy for diabetic ketoacidosis

Professor Mahesh Ramanan from The George Institute for Global Health and UNSW Medicine & Health has received $1.6 million for a fluid therapy trial for patients presenting with diabetic ketoacidosis.

Diabetic ketoacidosis (DKA) is a life-threatening complication of diabetes in which the body produces excess blood acids known as ketones. It occurs when there isn't enough insulin in the body and can be triggered by infection or other illness.

Fluid therapy is a vital component of the treatment of DKA, but which fluid provides the best outcomes is unknown. Saline is widely recommended in national and international guidelines despite a lack of high-quality evidence to support its use. It can lead to complications associated with worse outcomes in critically ill patients.

An alternative fluid, Plasma-Lyte 148 – a balanced salt solution that more closely matches the biochemistry of human blood – has theoretical advantages over saline and is recommended in some DKA guidelines.

“It is hoped that the results will provide definitive guidance on the best choice of fluid therapy in DKA and reduce healthcare costs by reducing the time patients need to spend in ICU and hospital,” Prof. Ramanan said.

Media enquiries

For enquiries about this story and interview requests please contact Yolande Hutchinson.

Tel: 0420 845 023 Email: [email protected]

Share this story

• Share this page on Email
• Share this page on Facebook
• Share this page on Twitter
• Share this page on LinkedIn
• Share this page on WhatsApp
• Share this page on FacebookMessenger
• Share this page on WeChat
• Share this page on Copy

Related stories

UNSW awarded over $17m in NHMRC clinical trials funding

UNSW researchers awarded $33m for medical research

UNSW receives $20m to support medical breakthroughs

Quick links

• Find funding
• Find publications
• News centre
• Outcomes of funding rounds
• Sapphire Login

MRFF – 2023 Stem Cell Therapies Grant Opportunity (GO6227)

MRFF – Stem Cell Therapies Mission – 2023 Stem Cell Therapies Grant Opportunity 

The Medical Research Future Fund (MRFF) – SCTM - 2023 Stem Cell Therapies Grant Opportunity will provide grants of financial assistance to support medical research and medical innovation projects that:

• a final product or therapy
• a feasible path to market
• an approach to regulatory processes
• a competitive advantage over comparable products
• appropriate consideration of the ethical, legal and social issues associated with treatments
• a strategy for enhancing sector capacity of key clinical, manufacturing and commercial skillsets
• potential funding leverage
• potential funding leverage Research projects may include:
• screening of novel or repurposed drug candidates, silencing RNAs or therapeutic oligonucleotides or other modifiers of cellular function, including gene editing and base editing
• personalised identification of appropriate drugs based on patient-specific stem cell–derived tissues

The anticipated outcome of the research is to improve the health and wellbeing of Australians by:

• Stream 1 (Accelerator): developing novel stem cell-based therapies that have the potential to transform clinical care
• Stream 2 (Accelerator): generating new treatments that can improve clinical care.

This grant opportunity is being administered by NHMRC on behalf of the Australian Government Department of Health and Aged Care.

Further information on MRFF is available from the Department of Health and Aged Care .

Link to GrantConnect

• Ideas Grants 2022 Peer reviewer briefing webinar introductions and presentation
• Indigenous Research Excellence Criteria video transcript
• Funding agreement and deed of agreement
• Institution approvals  
• Institutional Annual Compliance Report 
• Vary your grant
• Financial reporting
• Progress, final and additional reporting
• Direct Research Cost Guidelines
• Previous Personnel Support Package rates
• Previous Salary Support Package rates
• Institutional approvals and grant conditions
• Funding Agreement
• Financial Reports
• Scientific reporting and milestones
• Direct Research Costs and Personnel and Salary Support Packages
• Eligibility
• Peer review
• Research funding data
• Analysis of Australian health and medical research publications
• Medical Research Future Fund
• International Collaborative Health Research Funding
• Funding calendar
• Working together to support research
• Statements of Expectations
• Targeted Calls for Research
• Capacity and capability building and strengthening
• Health Advice and Publications
• Health effects of water fluoridation
• Preventing infection
• How NHMRC develops public health guidelines
• Complementary medicines
• Electronic cigarettes
• Myalgic Encephalomyelitis and Chronic Fatigue Syndrome
• Lead blood levels
• Recreational Water Quality Advisory Committee
• Australian Guidelines to Reduce Health Risks from Drinking Alcohol - Public submissions
• National Statement on Ethical Conduct in Human Research
• Genomics resources for clinicians and researchers
• Vitamin K for newborns
• Guidelines for Guidelines
• COVID-19 impacts
• Clinical trials reform
• Determining whether an embryo model is regulated by the ERLC
• Information for applicants
• Information for Licence Holders
• Mitochondrial Donation Licensing Scheme
• Training and Quality Assurance activities
• Import and export of cell lines
• Database of Licences issued
• Training and Quality Assurance
• Use of animals in NHMRC funded research
• The Human Research Ethics Applications (HREA)
• Ethical issues and further resources
• National Certification Scheme
• Human research ethics committees
• Clinical ethics
• Ethical guidelines for Assisted Reproductive Technology
• Ethical guidelines for research with Aboriginal and Torres Strait Islander Peoples
• NHMRC ethical guidelines on organ and tissue donation and transplantation
• Guideline development
• International engagement
• Research quality
• Research translation
• Research impact
• Dementia research
• NHMRC Special Initiative in Mental Health
• NHMRC’s role in addressing health implications of environmental change
• Submission of Targeted Calls for Research online pathway
• NHMRC health priorities 2021–2024
• Framework for Identifying and Prioritising Targeted Calls for Research
• Targeted Calls for Research Prioritisation Criteria Rubric
• Guide for Proposing Targeted Calls for Research
• Administering Institution Policy
• NHMRC Gender Equity Strategy 2022-2025
• Statement on sex and gender in health and medical research
• Structural priority funding and gender equity
• Accountability and reporting
• Fifteenth edition
• Fourteenth edition
• Ten of the Best Archive
• Ten of the Best
• 2022 Research Excellence Awards
• 2023 Research Excellence Awards
• Health Innovation Advisory Committee 2015-2018
• Legislative basis to NHMRC
• Senior executive and leadership team
• 2024–2027 Triennium Nominations: Embryo Research Licensing Committee
• Indigenous Research Ethics Guidelines Review Working Committee
• Natural Therapies Working Committee
• Publications
• Probity Event - Additional Guidance
• NHMRC Complaints Policy
• Temporary Employment Register
• Working at NHMRC
• How we select our people
• Indigenous internship program
• Freedom of information
• Child Safe Policy
• Annual reports and corporate plans
• Consumer and community engagement
• About the review
• Consumer Statement review
• Consumer and community representative involvement in the peer review process of Targeted Calls for Research